The Canonical Wnt/β-catenin Pathway as a Therapeutic Target in Multiple Myeloma

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

It has been more than 30 years since Nusse and Varmus identified a new mouse protooncogene int1 (integration 1), conserved across multiple species, and already recognised in Drosophila as Wingless (Wg). Wnts are now known to activate multiple signalling pathways, the best understood and extensively investigated being the canonical/β-catenin dependent pathway. β-catenin signalling has been found dysregulated to varying degrees and via multiple mechanisms in both solid and haematologic cancers, including multiple myeloma (MM). Recently developed inhibitors of the Wnt canonical pathway have proven to be potentially effective against MM, with minimal side effects. There is cautious optimism that some of these inhibitors will be added in our armamentarium against MM in the not so distant future. In this review, we discuss the possible mechanisms of Wnt-canonical pathway dysregulation in the pathogenesis of MM. Furthermore, we summarise the pathway inhibitors that have been validated in the disease in pre-clinical models or clinical trials and their potential challenges.
Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalArchives of Medical Research
Volume6
Issue number7
DOIs
Publication statusPublished - Jul 2018

Keywords

  • myeloma
  • Wnt signaling pathway
  • therapetic target

Cite this

@article{808a7dc2ccf0469d9029a43e558dd4ba,
title = "The Canonical Wnt/β-catenin Pathway as a Therapeutic Target in Multiple Myeloma",
abstract = "It has been more than 30 years since Nusse and Varmus identified a new mouse protooncogene int1 (integration 1), conserved across multiple species, and already recognised in Drosophila as Wingless (Wg). Wnts are now known to activate multiple signalling pathways, the best understood and extensively investigated being the canonical/β-catenin dependent pathway. β-catenin signalling has been found dysregulated to varying degrees and via multiple mechanisms in both solid and haematologic cancers, including multiple myeloma (MM). Recently developed inhibitors of the Wnt canonical pathway have proven to be potentially effective against MM, with minimal side effects. There is cautious optimism that some of these inhibitors will be added in our armamentarium against MM in the not so distant future. In this review, we discuss the possible mechanisms of Wnt-canonical pathway dysregulation in the pathogenesis of MM. Furthermore, we summarise the pathway inhibitors that have been validated in the disease in pre-clinical models or clinical trials and their potential challenges.",
keywords = "myeloma, Wnt signaling pathway, therapetic target",
author = "Ioanna Savvidou and Tiffany Khong and Andrew Spencer and Alt, {Karen Maria}",
year = "2018",
month = "7",
doi = "10.18103/mra.v6i7.1821",
language = "English",
volume = "6",
pages = "1--15",
journal = "Archives of Medical Research",
issn = "0188-4409",
publisher = "Elsevier",
number = "7",

}

The Canonical Wnt/β-catenin Pathway as a Therapeutic Target in Multiple Myeloma. / Savvidou, Ioanna; Khong, Tiffany; Spencer, Andrew; Alt, Karen Maria.

In: Archives of Medical Research, Vol. 6, No. 7, 07.2018, p. 1-15.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - The Canonical Wnt/β-catenin Pathway as a Therapeutic Target in Multiple Myeloma

AU - Savvidou, Ioanna

AU - Khong, Tiffany

AU - Spencer, Andrew

AU - Alt, Karen Maria

PY - 2018/7

Y1 - 2018/7

N2 - It has been more than 30 years since Nusse and Varmus identified a new mouse protooncogene int1 (integration 1), conserved across multiple species, and already recognised in Drosophila as Wingless (Wg). Wnts are now known to activate multiple signalling pathways, the best understood and extensively investigated being the canonical/β-catenin dependent pathway. β-catenin signalling has been found dysregulated to varying degrees and via multiple mechanisms in both solid and haematologic cancers, including multiple myeloma (MM). Recently developed inhibitors of the Wnt canonical pathway have proven to be potentially effective against MM, with minimal side effects. There is cautious optimism that some of these inhibitors will be added in our armamentarium against MM in the not so distant future. In this review, we discuss the possible mechanisms of Wnt-canonical pathway dysregulation in the pathogenesis of MM. Furthermore, we summarise the pathway inhibitors that have been validated in the disease in pre-clinical models or clinical trials and their potential challenges.

AB - It has been more than 30 years since Nusse and Varmus identified a new mouse protooncogene int1 (integration 1), conserved across multiple species, and already recognised in Drosophila as Wingless (Wg). Wnts are now known to activate multiple signalling pathways, the best understood and extensively investigated being the canonical/β-catenin dependent pathway. β-catenin signalling has been found dysregulated to varying degrees and via multiple mechanisms in both solid and haematologic cancers, including multiple myeloma (MM). Recently developed inhibitors of the Wnt canonical pathway have proven to be potentially effective against MM, with minimal side effects. There is cautious optimism that some of these inhibitors will be added in our armamentarium against MM in the not so distant future. In this review, we discuss the possible mechanisms of Wnt-canonical pathway dysregulation in the pathogenesis of MM. Furthermore, we summarise the pathway inhibitors that have been validated in the disease in pre-clinical models or clinical trials and their potential challenges.

KW - myeloma

KW - Wnt signaling pathway

KW - therapetic target

U2 - 10.18103/mra.v6i7.1821

DO - 10.18103/mra.v6i7.1821

M3 - Review Article

VL - 6

SP - 1

EP - 15

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-4409

IS - 7

ER -